Stem cells as the root of pancreatic ductal adenocarcinoma

被引:37
作者
Balic, Anamaria [1 ]
Dorado, Jorge [1 ]
Alonso-Gomez, Mercedes [1 ]
Heeschen, Christopher [1 ]
机构
[1] Spanish Natl Canc Res Ctr CNIO, Stem Cell & Canc Grp, Clin Res Programme, Madrid 28029, Spain
关键词
Pancreatic cancer; Cancer stem cells; Tumor-initiating cells; Inflammation; Targeted therapy; CIRCULATING TUMOR-CELLS; HEDGEHOG PATHWAY; CANCER-CELLS; SIGNALING PATHWAYS; DOWN-REGULATION; MOUSE MODEL; C-MET; CXCR4; GEMCITABINE; EXPRESSION;
D O I
10.1016/j.yexcr.2011.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Emerging evidence suggests that stem cells play a crucial role not only in the generation and maintenance of different tissues, but also in the development and progression of malignancies. For the many solid cancers, it has now been shown that they harbor a distinct subpopulation of cancer cells that bear stem cell features and therefore, these cells are termed cancer stem cells (CSC) or tumor-propagating cells. CSC are exclusively tumorigenic and essential drivers for tumor progression and metastasis. Moreover, it has been shown that pancreatic ductal adenocarcinoma does not only contain one homogeneous population of CSC rather than diverse subpopulations that may have evolved during tumor progression. One of these populations is called migrating CSC and can be characterized by CXCR4 co-expression. Only these cells are capable of evading the primary tumor and traveling to distant sites such as the liver as the preferred site of metastatic spread. Clinically even more important, however, is the observation that CSC are highly resistant to chemo- and radiotherapy resulting in their relative enrichment during treatment and rapid relapse of disease. Many laboratories are now working on the further in-depth characterization of these cells, which may eventually allow for the identification of their Achilles heal and lead to novel treatment modalities for fighting this deadly disease. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:691 / 704
页数:14
相关论文
共 108 条
[1]  
Ahlgren JD, 1996, CANCER-AM CANCER SOC, V78, P654
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]   Circulating tumour cells in clinical practice: Methods of detection and possible characterization [J].
Alunni-Fabbroni, Marianna ;
Sandri, Maria Teresa .
METHODS, 2010, 50 (04) :289-297
[4]   Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis [J].
Bankert, Richard B. ;
Balu-Iyer, Sathy V. ;
Odunsi, Kunle ;
Shultz, Leonard D. ;
Kelleher, Raymond J., Jr. ;
Barnas, Jennifer L. ;
Simpson-Abelson, Michelle ;
Parsons, Robert ;
Yokota, Sandra J. .
PLOS ONE, 2011, 6 (09)
[5]   Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[6]   Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse [J].
Bardeesy, N ;
Aguirre, AJ ;
Chu, GC ;
Cheng, KH ;
Lopez, LV ;
Hezel, AF ;
Feng, B ;
Brennan, C ;
Weissleder, R ;
Mahmood, U ;
Hanahan, D ;
Redston, MS ;
Chin, L ;
DePinho, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5947-5952
[7]   Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours [J].
Berman, DM ;
Karhadkar, SS ;
Maitra, A ;
de Oca, RM ;
Gerstenblith, MR ;
Briggs, K ;
Parker, AR ;
Shimada, Y ;
Eshleman, JR ;
Watkins, DN ;
Beachy, PA .
NATURE, 2003, 425 (6960) :846-851
[8]  
Brembeck FH, 2003, CANCER RES, V63, P2005
[9]  
Burger JA, 2009, EXPERT OPIN INV DRUG, V18, P481, DOI [10.1517/13543780902804249, 10.1517/13543780902804249 ]
[10]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413